SAB Biotherapeutics, Inc. announced that Breakthrough T1D awarded a grant to Michael J. Haller, M.D., at the University of Florida to support the PRISE-hATG clinical study. This study evaluates SAB-142 in patients with Stage 3 type 1 diabetes who are 100 days to two years from diagnosis. SAB Biotherapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for autoimmune diseases.